1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Adamas Pharmaceuticals Inc (ADMS)
  7. Quote

ADMS ADMS

Adamas Pharmaceuticals Stock Price

8.22
0.00 (0.0%)
Upgrade to Real-Time
Afterhours (Closed)
8.22
Volume 0
Bid Price 9.33
Ask Price 8.30
News -
Day High

Low
4.02

52 Week Range

High
9.15

Day Low
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
$52.04
Small Cap Pro
Monthly Subscription
for only
$49.05
DDE w/Realtime (Monthly)
Monthly Subscription
for only
$34.10
VAT not included
Company Name Stock Ticker Symbol Market Type
Adamas Pharmaceuticals Inc ADMS NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.0% 8.22 19:00:00
Open Price Low Price High Price Close Price Prev Close
8.22 8.22
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 8.22 USD

Period:

Draw Mode:

Adamas Pharmaceuticals Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 376.37M 45.79M 40.85M $ 74.46M $ -52.84M -2.02 -4.80
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - - 3.90%

more financials information »

Adamas Pharmaceuticals News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical ADMS Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.000.000.000.0000.000.0%
1 Month8.178.258.118.19898,6300.050.61%
3 Months4.568.254.467.951,455,8403.6680.26%
6 Months5.208.254.027.36785,2603.0258.08%
1 Year4.809.154.026.60648,2503.4271.25%
3 Years10.5012.571.905.94528,417-2.28-21.71%
5 Years15.6744.001.9014.02561,854-7.45-47.54%

Adamas Pharmaceuticals Description

Adamas Pharmaceuticals Inc discovers, develops, and sells therapies for chronic neurologic disorders. The company's approved/commercial product is GOCOVRI, an amantadine therapy for the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease. It operates in one reportable segment: the development and commercialization of therapeutics targeting chronic disorders of the central nervous system. The company generates its revenues primarily from the United States.


Your Recent History
NASDAQ
ADMS
Adamas Pha..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.